Homocystein - An independent risk factor for cardiovascular and thrombotic diseases;Homocystein - Ein unabhängiger risikofaktor für kardiovaskuläre und thrombotische erkrankungen

Therapeutische Umschau

Volumn 62, Issue 9, 2005, Pages 641-646

  Fowler, Brian ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; METHIONINE; METHYL GROUP; PYRIDOXINE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; DIETARY INTAKE; DISEASE MARKER; ENVIRONMENTAL FACTOR; FOLATE METABOLISM; GENETIC POLYMORPHISM; HIGH RISK POPULATION; HUMAN; HYPERHOMOCYSTEINEMIA; ISCHEMIC HEART DISEASE; NUTRITION; PERIPHERAL VASCULAR DISEASE; REVIEW; RISK FACTOR; SCREENING; THROMBOSIS;

EID: 25144513395     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930.62.9.641     Document Type: Review

References (11)

1. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-57.
2. Homocysteine Studies Collaboration: Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002; 288: 2015-22.
3. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002: 1202.
4. Refsum H, Smith AD, Ueland PM, Nexo E, Clarke R, McPartlin J, Johnston C, Engbaek F, Schneede J, McPartlin C, Scott JM. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem 2004; 50: 3-32. Review.
5. Stanger O, Herrmann W, Pietrzik K, Fowler B, Geisel J, Dierkes J, Weger M. Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases. Z Kardiol 2004; 93: 439-53. Review.
6. Fowler B. Disorders of homocysteine metabolism. J Inherit Metab Dis 1997; 20: 270-285.
7. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG. MTHFR Studies Collaboration Group. MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 2002; 288: 2023-31.
8. Schnyder G, Roffi M, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001; 345: 1593-600.
9. Fowler B. Homocystein als kardiovasculärer Risikofaktor. Kardiovasculäre Medizin 2004; 7: 71-77.
10. Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost 2005; 3: 292-9.
11. Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 1997; 95: 1777-82.